A Phase 2 interventional study of Hydroxycarbamide and Placebo Oral Tablet in Sickle Cell Disease, sponsored by Theravia. Completed at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Theravia (part of Norgine) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing hydroxyurea in Anemia, Sickle Cell — 8 open to participants now, 14 under way, 1 of them phase 3. Hydroxyurea · Anemia, Sickle Cell.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, this one is the 24th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2019, is one of 20 in phase 2, and was the 44th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →8 of the 59 studies testing hydroxyurea in Anemia, Sickle Cell are open now, in 6 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 11–18
Theravia · Sites in France, French Guiana
Ages 9 mo–11 yrs
Vanderbilt University Medical Center · Sites in Nigeria
Ages 5–12
Brown University · Sites in Angola
Ages 6 mo–12 yrs
By country, each count listing its studies:
Hydroxyurea: first FDA approval 1967 (DROXIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 29 · Phase 3 12 · Phase 4 5
First in 1984; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 50 across the 57 interventional studies. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Theravia, one of the names counted as Norgine. Under that name alone:
Theravia is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Norgine has 7 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
4 of the studies testing hydroxyurea in Anemia, Sickle Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT02286154Children's Hospital Medical Center, CincinnatiTherapeutic Response Evaluation and Adherence Trial (TREAT) | 2026-12 |
| NCT05662098Children's Hospital Medical Center, CincinnatiAlternative Dosing And Prevention of Transfusions (ADAPT) | 2026-12-31 |
| NCT06171217Children's Hospital Medical Center, CincinnatiRealizing Effectiveness Across Continents With Hydroxyurea | 2027-10-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this phase IIb, international, multicentre, double-blind, randomised, placebo-controlled study is to determine the effect of hydroxycarbamide on albuminuria after 6 months of treatment in SCD adult patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months. Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial.
Drug: Hydroxycarbamide
Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months. Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial.
Drug: Placebo Oral Tablet
Hydroxycarbamide tablets of 100 and 1000 mg
Also known as: Siklos
Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value
The primary endpoint of this study is the proportion of patients in the hydroxycarbamide and placebo groups achieving at least a 30% decrease in ACR baseline value at 6 months after treatment initiation. Patients who do not achieve at least a 30% decrease of the ACR baseline value at month 6 will be considered non-responders.
Time frame: 6 months
Absolute Mean Changes in eGFR Value
Time frame: 6 months
Absolute Mean Changes in ACR Value
Time frame: 6 months
Proportion of Patients With a Shift From Macroalbuminuria to Microalbuminuria
Time frame: 6 months
Proportion of Patients With a Shift From Microalbuminuria to Normoalbuminuria
Time frame: 6 months
Proportion of Patients With a Shift From Macroalbuminuria to Normoalbuminuria
Time frame: 6 months
Proportion of Patients With a Shift From Microalbuminuria to Macroalbuminuria
Time frame: 6 months
Absolute Mean Changes of Systolic Blood Pressure
Time frame: 6 months
Absolute Mean Changes of Body Weight
Time frame: 6 months
Absolute Mean Changes of Diastolic Blood Pressure
Time frame: 6 months
Absolute Mean Changes of Heart Rate Measure
Time frame: 6 months
Absolute Mean Changes in White Blood Cells Count
Time frame: 6 months
Absolute Mean Changes in Platelets Count
Time frame: 6 months
Absolute Mean Changes in Mean Corpuscular Volume
Time frame: 6 months
Absolute Mean Changes in Mean Corpuscular Haemoglobin Concentration
Time frame: 6 months
Absolute Mean Changes in Mean Corpuscular Haemoglobin
Time frame: 6 months
Absolute Mean Changes in Hemoglobin Count
Time frame: 6 months
Absolute Mean Changes in Foetal Hemoglobin Count
Time frame: 6 months
Absolute Mean Changes in Free Hemoglobin Count
Time frame: 6 months and 12 months for responder patients willing to continue the study after month 6.
Absolute Mean Changes in Dense Red Blood Cells Percentage
Time frame: 6 months and 12 months for responder patients willing to continue the study after month 6.
Absolute Mean Changes in Endogenous Erythropoietin Count
Time frame: 6 months
Absolute Mean Changes in Ferritin Count
Time frame: 6 months
Absolute Mean Changes in Lactate Dehydrogenase
Time frame: 6 months
Absolute Mean Changes in Aspartate Aminotransferase
Time frame: 6 months
Absolute Mean Changes in Alanine Amino Transferase
Time frame: 6 months
Absolute Mean Changes in Blood Urea Nitrogen
Time frame: 6 months
Absolute Mean Changes in Conjugated Bilirubin
Time frame: 6 months
Absolute Mean Changes in Total Bilirubin
Time frame: 6 months
Absolute Mean Changes in Reticulocytes
Time frame: 6 months
From 28 May 2019 to 30 May 2024, 86 patients were included in the study in the mITT population and analysed in France and Africa (Mali, Ivory Coast and Senegal).
| Milestone | Hydroxycarbamide | Placebo |
|---|---|---|
| Started | 46 | 40 |
| Completed | 44 | 38 |
| Not completed | 2 | 2 |
| Milestone | Hydroxycarbamide | Placebo |
|---|---|---|
| Started | 18 | 15 |
| Completed | 15 | 9 |
| Not completed | 3 | 6 |
The primary endpoint of this study is the proportion of patients in the hydroxycarbamide and placebo groups achieving at least a 30% decrease in ACR baseline value at 6 months after treatment initiation. Patients who do not achieve at least a 30% decrease of the ACR baseline value at month 6 will be considered non-responders.
| Participants | Hydroxycarbamide | Placebo |
|---|---|---|
| Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value | 18 | 15 |
| ml/min/1.73m2 | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in eGFR Value | 3.2 ± 18.5 | -1.0 ± 13.8 |
| mg/mmol | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in ACR Value | 3.5 ± 19.7 | 1.0 ± 13.1 |
| Participants | Hydroxycarbamide | Placebo |
|---|---|---|
| Proportion of Patients With a Shift From Macroalbuminuria to Microalbuminuria | 1 | 2 |
| Participants | Hydroxycarbamide | Placebo |
|---|---|---|
| Proportion of Patients With a Shift From Microalbuminuria to Normoalbuminuria | 10 | 7 |
| Participants | Hydroxycarbamide | Placebo |
|---|---|---|
| Proportion of Patients With a Shift From Macroalbuminuria to Normoalbuminuria | 1 | 0 |
| Participants | Hydroxycarbamide | Placebo |
|---|---|---|
| Proportion of Patients With a Shift From Microalbuminuria to Macroalbuminuria | 3 | 3 |
| mmHg | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes of Systolic Blood Pressure | 2.8 ± 10.7 | 2.2 ± 13.1 |
| kg | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes of Body Weight | 2.2 ± 3.0 | -0.3 ± 2.1 |
| mmHg | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes of Diastolic Blood Pressure | 2.5 ± 13.3 | -1.0 ± 12.9 |
| beats/minute | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes of Heart Rate Measure | -2.1 ± 11.3 | 2.4 ± 12.5 |
| cells/mm3 | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in White Blood Cells Count | -3659.6 ± 3524.4 | -228.4 ± 2982.1 |
| 10^9 platelets per liter | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Platelets Count | -49.3 ± 150.9 | -16.0 ± 83.5 |
| fL | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Mean Corpuscular Volume | 15.1 ± 10.8 | -0.3 ± 3.4 |
| g/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Mean Corpuscular Haemoglobin Concentration | 1.7 ± 15.8 | -4.8 ± 16.4 |
| pg | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Mean Corpuscular Haemoglobin | 5.5 ± 4.0 | -0.8 ± 1.6 |
| g/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Hemoglobin Count | 12 ± 11.3 | -2.2 ± 6.1 |
| percentage of hemoglobin | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Foetal Hemoglobin Count | 8.5 ± 8.8 | 0.3 ± 1.9 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
| U/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Endogenous Erythropoietin Count | -8.2 ± 22.1 | 17.4 ± 37.1 |
| µg/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Ferritin Count | 28.1 ± 664.2 | -8.0 ± 404.3 |
| U/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Lactate Dehydrogenase | -170.5 ± 349.4 | -1.8 ± 220.9 |
| U/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Aspartate Aminotransferase | -8.7 ± 19.2 | -1.0 ± 10.9 |
| U/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Alanine Amino Transferase | -1.7 ± 51.2 | -0.2 ± 13.7 |
| mmol/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Blood Urea Nitrogen | -0.5 ± 6.4 | 0.5 ± 2.6 |
| µmol/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Conjugated Bilirubin | -0.7 ± 33.8 | -1.9 ± 9.8 |
| µmol/L | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Total Bilirubin | -8.9 ± 106.5 | 4.7 ± 30.1 |
| cells/mm3 | Hydroxycarbamide | Placebo |
|---|---|---|
| Absolute Mean Changes in Reticulocytes | -116082.5 ± 168548.6 | -35336.1 ± 108156.3 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hydroxycarbamide | 0/46 (0%) | 5/46 (10.9%) | 30/46 (65.2%) |
| Placebo | 2/40 (5%) | 7/40 (17.5%) | 29/40 (72.5%) |
| Event | Hydroxycarbamide | Placebo |
|---|---|---|
| SICKLE CELL ANAEMIA WITH CRISISBlood and lymphatic system disorders | 2/46 | 2/40 |
| ACUTE CHEST SYNDROMERespiratory, thoracic and mediastinal disorders | 0/46 | 2/40 |
| ANAEMIABlood and lymphatic system disorders | 0/46 | 1/40 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/46 | 1/40 |
| INFLUENZAInfections and infestations | 0/46 | 1/40 |
| PNEUMONIAInfections and infestations | 0/46 | 1/40 |
| HEPATOBILIARY PROCEDURAL COMPLICATIONInjury, poisoning and procedural complications | 0/46 | 1/40 |
| BONE INFARCTIONMusculoskeletal and connective tissue disorders | 0/46 | 1/40 |
| CHOLECYSTITISHepatobiliary disorders | 1/46 | 0/40 |
| CHOLELITHIASISHepatobiliary disorders | 1/46 | 0/40 |
| Event | Hydroxycarbamide | Placebo |
|---|---|---|
| SICKLE CELL ANAEMIA WITH CRISISBlood and lymphatic system disorders | 3/46 | 7/40 |
| HEADACHENervous system disorders | 8/46 | 5/40 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 5/46 | 6/40 |
| ASTHENIAGeneral disorders | 2/46 | 5/40 |
| VERTIGOEar and labyrinth disorders | 3/46 | 5/40 |
| CHEST PAINGeneral disorders | 1/46 | 4/40 |
| PYREXIAGeneral disorders | 4/46 | 1/40 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 4/46 | 3/40 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/46 | 3/40 |
| FATIGUEGeneral disorders | 1/46 | 3/40 |
| Age, Continuous(years) | Hydroxycarbamide | Placebo | Total |
|---|---|---|---|
| Mean | 30.3 ± 10.0 | 30.0 ± 8.7 | 30.2 ± 9.3 |
| Sex: Female, Male(Participants) | Hydroxycarbamide | Placebo | Total |
|---|---|---|---|
| Female | 32 | 27 | 59 |
| Male | 14 | 13 | 27 |
| Race/Ethnicity, Customized(Participants) | Hydroxycarbamide | Placebo | Total |
|---|---|---|---|
| Continent of origin — Africa - America | 45 | 40 | 85 |
| Continent of origin — Other | 1 | 0 | 1 |
| Region of Enrollment(participants) | Hydroxycarbamide | Placebo | Total |
|---|---|---|---|
| Senegal | 17 | 12 | 29 |
| Mali | 12 | 8 | 20 |
| Guadeloupe | 0 | 1 | 1 |
| Côte D'Ivoire | 5 | 4 | 9 |
| Martinique | 1 | 0 | 1 |
| France | 11 | 15 | 26 |
| SCD genotype(Participants) | Hydroxycarbamide | Placebo | Total |
|---|---|---|---|
| HbSS | 43 | 37 | 80 |
| HbSbeta0 | 3 | 3 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in May 2024, 60 months.
Results were first posted in May 2025, 11 months after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 60 months is above that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydroxyurea